March 21st, 2024: Ozempic litigation enters preliminary phase as lawsuits target Eli Lilly and Novo Nordisk The litigation surrounding Ozempic and other weight loss drugs is currently in the preliminary phase, and the number of lawsuits is expected to grow as the court sets the guidelines for filing cases
This medication is NOT recommended if you: Have a personal or family history of medullary thyroid cancer Have Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Are pregnant, breastfeeding, or planning pregnancy Have severe gastrointestinal conditions like gastroparesis Me before Weight Loss Injections at 180 lbs
FDA Approves Ozempic (Semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults With Type 2 Diabetes and Chronic Kidney Disease
Pre-treatment Tests to be Performed: Blood Panels: A doctor must check baseline levels of IGF-1, fasting blood sugar, and thyroid function to ensure the patient is a safe candidate
A pivotal shift occurred on December 1, 2025, when the World Health Organization (WHO) released its first-ever clinical guidelines recommending GLP-1 receptor agonists for the long-term treatment of obesity
Rushing the process can do more harm than good
